MGP Ingredients's (NASDAQ:MGPI) Q1 Sales Top Estimates
Food and beverage supplier MGP Ingredients (NASDAQ:MGPI) beat Wall Street's revenue expectations in Q1 CY2025, but sales fell by 28.7% year on year to $121.7 million. The company expects the full year's revenue to be around $530 million, close to analysts' estimates. Its non-GAAP profit of $0.36 per share was 3.7% below analysts' consensus estimates.
Is now the time to buy MGP Ingredients? Find out in our full research report.
Revenue: $121.7 million vs analyst estimates of $117.5 million (28.7% year-on-year decline, 3.5% beat)
Adjusted EPS: $0.36 vs analyst expectations of $0.37 (3.7% miss)
Adjusted EBITDA: $21.76 million vs analyst estimates of $19.54 million (17.9% margin, 11.3% beat)
The company reconfirmed its revenue guidance for the full year of $530 million at the midpoint
Management reiterated its full-year Adjusted EPS guidance of $2.60 at the midpoint
EBITDA guidance for the full year is $110 million at the midpoint, above analyst estimates of $107.9 million
Operating Margin: -0.6%, down from 17% in the same quarter last year
Free Cash Flow was $24.76 million, up from -$2.4 million in the same quarter last year
Market Capitalization: $626.8 million
'We are pleased with first quarter results that keep us on track to meet our full-year guidance. While elevated industry-wide barrel whiskey inventories and a cautious consumer environment remain as headwinds, we saw signs of positive progress across all three of our business segments. These early signs of stabilization give us confidence that the proactive actions we are taking are beginning to take hold,' said Brandon Gall, Interim President and CEO, and CFO.
Headquartered in Atchison, Kansas, MGP Ingredients (NASDAQ:MGPI) is a leading supplier of high-quality ingredients to the food and beverage industry
A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years.
With $654.7 million in revenue over the past 12 months, MGP Ingredients is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.
As you can see below, MGP Ingredients's revenue declined by 2.8% per year over the last three years, a tough starting point for our analysis.
This quarter, MGP Ingredients's revenue fell by 28.7% year on year to $121.7 million but beat Wall Street's estimates by 3.5%.
Looking ahead, sell-side analysts expect revenue to decline by 20% over the next 12 months, a deceleration versus the last three years. This projection is underwhelming and implies its products will see some demand headwinds.
Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
MGP Ingredients has shown decent cash profitability, giving it some flexibility to reinvest or return capital to investors. The company's free cash flow margin averaged 6.5% over the last two years, slightly better than the broader consumer staples sector.
Taking a step back, we can see that MGP Ingredients's margin expanded by 4.3 percentage points over the last year. This shows the company is heading in the right direction, and we can see it became a less capital-intensive business because its free cash flow profitability rose while its operating profitability fell.
MGP Ingredients's free cash flow clocked in at $24.76 million in Q1, equivalent to a 20.4% margin. Its cash flow turned positive after being negative in the same quarter last year, building on its favorable historical trend.
We were impressed by how significantly MGP Ingredients blew past analysts' EBITDA expectations this quarter. We were also glad its gross margin outperformed Wall Street's estimates. On the other hand, its EPS missed. Overall, this quarter had some key positives. The stock traded up 3.3% to $30.42 immediately after reporting.
MGP Ingredients had an encouraging quarter, but one earnings result doesn't necessarily make the stock a buy. Let's see if this is a good investment. The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
39 minutes ago
- Yahoo
Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO
-- Insurance technology company Slide is pursuing a valuation of up to $2.12 billion in its upcoming initial public offering (IPO) on the Nasdaq exchange. The company disclosed the target in a filing on Monday. In collaboration with some of its existing stakeholders, Slide is aiming to raise up to $340 million from the IPO. This move is in line with a recent trend of successful stock market debuts by insurance firms. Barclays and Morgan Stanley have been named as the lead underwriters for the listing. The shares of the company are anticipated to begin trading on the Nasdaq exchange under the ticker symbol "SLDE". Related articles Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO Morgan Stanley downgrades Lululemon on weak US growth outlook Tesla shares slip after double downgrade amid Trump feud fallout Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
39 minutes ago
- Yahoo
Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr
-- Texas Capital has downgraded Sitio Royalties Corp (NYSE:STR) to Hold from Buy after the company agreed to be acquired by Viper Energy (NASDAQ:VNOM) in an all-stock transaction valued at $19.41 per share. The downgrade comes as analysts no longer see material upside following the announced deal, which values Sitio at about $4.1 billion. Texas Capital also cut its price target on Sitio to $20 from $29, in line with the proposed merger terms. 'We are positive on the transaction,' analysts wrote, citing strategic fit, increased scale, low leverage, and an attractive base dividend breakeven below $20 per barrel WTI. 'The combination creates a must-own Minerals company.' Texas Capital does not expect any competing bids given the lack of well-capitalized public rivals in the space. Viper Energy said the deal will make it the largest public mineral and royalty company in the U.S., with positions in the Permian and other key basins. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. Related articles Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr Tesla shares gain as Trump wishes Musk 'well' GFL weighs sale in infrastructure arm valued at C$5 billion - Bloomberg Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data